News
DRMA
0.6609
-7.57%
-0.0541
Dermata Therapeutics GAAP EPS of -$0.55 in-line
Seeking Alpha · 2d ago
Dermata Therapeutics Q3 EPS $(0.55), Inline
Benzinga · 2d ago
Weekly Report: what happened at DRMA last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at DRMA last week (1026-1030)?
Weekly Report · 11/02 10:09
Dermata Therapeutics Advances Tome Clearing Acne Treatment
TipRanks · 10/29 21:48
Dermata initiates acne clinical trial of second Tome skincare product
TipRanks · 10/29 21:10
Dermata Therapeutics Enrolls First Participant In Its Clinical Trial Evaluating Tome Clearing Treatment For Acne; Expects To Launch This Second Commercial Product In H1 2027
Benzinga · 10/29 20:27
Weekly Report: what happened at DRMA last week (1019-1023)?
Weekly Report · 10/26 10:09
Weekly Report: what happened at DRMA last week (1012-1016)?
Weekly Report · 10/19 10:09
Why Is Dermata Therapeutics Stock Gaining Thursday?
Benzinga · 10/15 17:29
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/15 17:05
Dermata announces results from study evaluating Tome Foundational Treatment
TipRanks · 10/15 12:20
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Benzinga · 10/15 12:10
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Barchart · 10/15 07:05
Weekly Report: what happened at DRMA last week (1005-1009)?
Weekly Report · 10/12 10:14
Dermata Therapeutics registers to sell 6.92M shares of common stock for holders
TipRanks · 10/09 20:11
Weekly Report: what happened at DRMA last week (0928-1002)?
Weekly Report · 10/05 10:13
Weekly Report: what happened at DRMA last week (0921-0925)?
Weekly Report · 09/28 10:09
Weekly Report: what happened at DRMA last week (0914-0918)?
Weekly Report · 09/21 10:09
Weekly Report: what happened at DRMA last week (0907-0911)?
Weekly Report · 09/14 10:14
More
Webull provides a variety of real-time DRMA stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.